RECRUITING

Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors

Talk to us

Conditions

CancerMetastatic CancerLocally AdvancedLocally Advanced Solid TumorLocally Advanced CarcinomaRadiationRadiotherapyBulkySpatial fractionationLattice therapyPalliativePalliation

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this research study is to determine if lattice radiation therapy (LRT) will provide better treatment for bulky (large) tumors than current standard of care radiotherapy.

Official Title

A Phase 2 Study of Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors

Quick Facts

Study Start:2024-08-02
Study Completion:2027-06-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06416007

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Solid tumor malignancy with a clinical indication for radiation
  2. * Patients must have measurable disease
  3. * Target lesion(s) which are amenable to lattice therapy plan
  4. * When applicable, target lesion for radiation amenable to immobilization during delivery of radiotherapy
  5. * Age ≥18 years.
  6. * ECOG Performance status ≤2
  7. * Life expectancy greater than 3 months
  8. * Women of child-bearing potential and men must agree to avoid conception via abstinence (ideal) or a method of birth control (e.g., hormonal or barrier method of birth control) prior to study entry and for at least 30 days after completion of lattice therapy administration.
  9. * Ability to understand and the willingness to sign a written informed consent document
  1. * Patients receiving cytotoxic chemotherapy or known radiosensitizing agents within 5 days before or after lattice therapy.
  2. * Patients with hematologic malignancies including lymphoma and leukemia as well as primary or metastatic central nervous system (CNS) malignancies.
  3. * Patients with a history of conditions which predispose them to increased radiation toxicity
  4. * Patients with known contraindications to radiation therapy
  5. * Patients with uncontrolled intercurrent illness
  6. * Pregnant women

Contacts and Locations

Study Contact

UCCC Clinical Trials Office
CONTACT
513-584-7698
cancer@uchealth.com
Andrew Frankart, MD
CONTACT

Study Locations (Sites)

University of Cincinnati Medical Center
Cincinnati, Ohio, 45219
United States

Collaborators and Investigators

Sponsor: University of Cincinnati

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-08-02
Study Completion Date2027-06-01

Study Record Updates

Study Start Date2024-08-02
Study Completion Date2027-06-01

Terms related to this study

Keywords Provided by Researchers

  • Radiation
  • Radiotherapy
  • Bulky
  • Spatial fractionation
  • Lattice therapy
  • Palliative
  • Palliation

Additional Relevant MeSH Terms

  • Cancer
  • Metastatic Cancer
  • Locally Advanced
  • Locally Advanced Solid Tumor
  • Locally Advanced Carcinoma